ResMed: Near-Term Upside From Philips Withdrawal, Seeking $35 Per Share Return Objective

Jun. 07, 2022 10:31 AM ETResMed Inc. (RMD)RSMDF1 Comment
Zach Bristow profile picture
Zach Bristow


  • ResMed presents with near-term upside potential not yet reflected by the market.
  • The upside case is bolstered by a key competitor's withdrawal from the market until 2023 at least.
  • This adds to the certainty of RMD's future cash flows and underpins interesting economics in the company's forward sales estimates.
  • We are seeking a return objective of $35 per share with a speculative buy rating, aiming to capture the near-term catalyst listed above.

Doctor diagnose virtual human lungs innovation and medical technology. Healthcare and medicine concept.

KTStock/iStock via Getty Images

Investment Summary

We are constructive on ResMed Inc. (NYSE:RMD) shares noting there is near-term upside potential to be unlocked from competitor Philips' subsidiary, Respironics', device recall. With the competitor removed from the flow generator

RMD 12-month price performance

Data & Image Source: Bloomberg

RMD's gross margins have narrowed in recent times

Data: Bloomberg; Image Source: Hummingbird Insights LP

FCF History & Estimates

Data: Bloomberg; Image Source: Hummingbird Insights LP

Changes in working capital Q1 2020 - Q3 2022

Data: Bloomberg; Image Source: Hummingbird Insights LP

Hummingbird insights

Data & Image: Hummingbird Insights LP

RMD FCF Marginal analysis

Data: Bloomberg; Image: Hummingbird Insights LP

This article was written by

Zach Bristow profile picture
Buy side equity portfolio strategist serving mandates throughout EU/US/APAC. Helping you position your portfolios for the future is my top priority. Shoot me a message to discuss trade ides or talk portfolio construction. Disclaimer:The opinions expressed in all articles do not constitute as investment advice. Please remember to conduct your own due diligence.

Disclosure: I/we have a beneficial long position in the shares of RMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.